PETHEDINE

Pethidine (Meperidine hydrochloride) - 50 mg/1ml, 100 mg/2ml For hospital use only. I.M./S.C. Injection/Slow I.V injection/I.V. Infusion

Category:

Analgesic, opioid (1)

Indication:

Management of moderate to severe pain; preoperative sedation, and obstetrical analgesia.

Contraindication:

Hypersensitivity to meneridine or any component of the formulation; use with or within 14 days of MAO inhibitors; severe respiratory insufficiency.(1)

Warning:

- -Should not be used for acute/cancer pain because of the risk of neurotoxicity.
- -Avoid using meperidine for pain control, especially in the elderly and renally impaired patients.
- -May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness such as driving.
- -Use only with extreme caution (if at all) in patients with head injury or increased intracranial pressure.
- -Avoid use in patients with CNS depression or coma.
- -Use with extreme caution in patients having an acute asthma attack, with chronic obstructive pulmonary disease or cor pulmonale. kyphoscoliosis or other skeletal disorder which may alter respiratory function.
- -Inform your doctor if you have any illnesses such as; hepatic, renal and/or pulmonary disorders, thromboembolic and vein disorders, biliary tract infection, acute dyspnea, prostate malignancy, hypothyroidism, pancreatitis, fluctuations in blood pressure. -The long-term use of this drug may result in dependence.
- -The intravenous injection of this drug should be very slow; otherwise it may cause allergic reactions such as shortness of breath. hypotension, severe weakness, and cardiac arrest.

Pregnancy and lactation considerations:

The use of this drug is in Group C during pregnancy, it should be used with caution and under the supervision of your doctor. (2) In lactating women, it is not recommended due to its secretion in the milk, use under the supervision of your doctor. (2)

Drug interaction:

Avoid concomitant use of meperidine with: Azelastine, Dapoxetine, MAO inhibitors (for patients who have received these drugs within previous 14 days), Mixed agonist/antagonist opioids, Orphenadrine; Thalidomide

Meperidine may increase the levels/effects of: Alcohol; Antipsychotic agents; CNS depressants; Desmopressin; Diuretics, Metoclopramide; Metyrosine;

Pramipexole: Zolpidem: Serotonin modulators.

The levels of Megeridine may increase by amphetamines; Anticholinergic agents; Antiemetic agents; Brimonidine (topical)T magnesium sulfate; Minocycline; Proteas inhibitors

The levels of Meperidine may be decreased by: Ammonium chloride; Fosphenytoin; Naltrexone⁽¹⁾

Monitoring parameters:

Pain relief, respiratory and mental status, blood pressure, observe patient for excessive sedation, CNS depression, Seizures, respiratory depression; signs and symptoms of hypogonadism or hypoadrenalism.

Dosing:

Note: adjustment in the dose and frequency, and duration of meperidine therapy may be necessary in patients with hepatic and/or renal impairment.

Pain, moderate to severe (analgesic): IM, SubQ: 50 to 150 mg every 3 to 4 hours as needed.

Preoperatively: IM. SubO: 50 to 100 mg given 30 to 90 minutes before the beginning of anesthesia

Obstetrical analgesia: IM, SubO: 50 to 100 mg when pain becomes regular; may repeat at every 1 to 3 hour intervals.

I.V. Infusion injection should be diluted up to 1 mg/ml

Geriatric: avoid use

Pediatric Note:

Use of Meperidine as an analgesic is not recommended. If use in acte pain (in patients without renal or CNS disease) can not be avoided, treatment should be limited to <48 hours.

Pain, moderate to severe (analgesic): IM, SubQ: 1.1 to 1.8 mg/kg/dose every 3 to 4 hours as needed (maximum 50 to 150 mg/dose) Renal impairment: Avoid use in renal impairment

Hepatic Impairment: Use with caution in severe hepatic impairment; consider a lower initial dose when initiating therapy. An increased opioid effect may be seen in patients with cirrhosis; dose reduction is more important for the oral than IV rout^(1,2) Adverse effects:

Note: Concomitant use of this drug with alcohol or sedative medications increases its effect.

Common side effects:

- Dermatologic: Inflammation at the injection site, skin complications such as Have, itching, rash, Diaphoresis, Pruritus, urticaria -Gastrointestinal: Biliary colic, Nausea and vomiting, spasm of sphincter of Oddi, constipation
- -Genitourinary: Urinary retention

Henatic: Liver function test increased -

-Renal effects: acute renal failure. Increased BUN, increased creating

-Other complications: Confusion, hallucination, anxiety, visual impairment, tremor, weakness, insomnia, anorexia, dizziness, ataxia, decreased blood pressure, abdominal pain, jaundice, blood disorders (anemia, leukocytosis, neutropenia, thrombocytopenia), blood in the urine and thrombocytopenic purpura / hemolytic uremic syndrome (TTP / HUS). (1,3)

Storage condition:

- -Take the product immediately after preparation and dilution and dispose the remained of the drug.
- -Avoid use of medicine in case of crystallization or turbidity.
- -Keep out of the reach of children.
- -Store below 30°C.
- -Do not keep the prepared and diluted solution in the refrigerator.(1)

Each Ampoule (1&2 ml) contains Pethidine Hydrochloride 50mg/1ml, 100 mg/2ml manufactured by Exir pharmaceutical company. available in 1 box containing 10 ampules of Pethedine.

- 1. Lexi comp Drug information handbook, 2017, 25th edition, Pages: 1631-1633
- 2. Drug facts and comparisons, 2012, Pages: 1347
- 3. AHFS Drug information 2010, Pages: 2178-2180



